We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

DxGen Corp.

DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculo... read more Featured Products: More products

Download Mobile App





Automatic Point-of-Care System Measures COVID-19 Antibodies Along with HbA1c, CRP, U-Albumin within 3 Minutes

By LabMedica International staff writers
Posted on 06 Oct 2020
A new automatic point-of-care system measures COVID-19 antibodies along with HbA1c, glycated albumin, hemoglobin, C-reactive protein and U-Albumin within just three minutes.

DxGen Corp. More...
(Korea) has launched the Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit, which allows to easily test IgM/IgG antibodies to SARS-CoV-2. The Epithod SARS-CoV-2 qAb is a vitro diagnostic (IVD) test that can detect IgM and IgG antibodies produced after virus infection in human whole blood and serum/plasma. According to DxGen, the Epithod SARS-CoV-2 qAb test kit has a sensitivity and specificity of 97% and 100%, respectively at 95% confidence intervals.

The test kit is a gold nanoparticle-based immunoassay for semi-quantitative determination with the easy-to-use Epithod AutoDx analyzer. Users can put the test kit and specimen on the tray and press a button, after which the analyzer perform the entire test process automatically. A key benefit of the Epithod AutoDx analyzer is that in addition to measuring IgM/IgG antibodies to SARS-CoV-2, it can also measure various underlying diseases test markers such as HbA1c, glycated albumin, hemoglobin, C-reactive protein, U-Albumin, etc. By providing medical professionals with various and valuable diagnostic information, the Epithod system can be effectively used not only for COVID-19 diagnosis tests, but also for complication diagnosis tests and patient prognosis monitoring and treatment in various medical front lines.

"We are currently processing the FDA EUA, and we have plan to quickly add test kits such as D-dimer, COVID-19 Antigen, Influenza A/B, etc.," said Dr. Jinwoo Lee, CEO of DxGen Corp.




Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.